In a potentially major advancement in cardiac care using ECG testing, Southlake medtech HeartSciences has been granted a patent by the United States Patent and Trademark Office for the “ECG Quantification of Echocardiographic Measurements of Diastolic Function of the Heart” using of AI technology.
Heart Test Laboratories, doing business as HeartSciences, is focused on applying AI-based technology to an ECG (also known as an EKG) to dramatically expand and improve clinical utility of an ECG by detecting cardiac dysfunction, which has been recognized as one of the earliest signs of heart disease. Typically, its onset occurs when a patient is still asymptomatic, according to the company.
HeartSciences’ first device, the MyoVista wavelet ECG, leverages AI machine learning to detect cardiac dysfunctions that cannot be diagnosed by current conventional ECGs. The company said its first algorithm is designed to provide diagnostic information related to impaired cardiac relaxation associated with diastolic dysfunction along with all conventional ECG information, all in a single test.
A quick test can be performed in a wide range of settings
“The ECG is a ubiquitous, relatively inexpensive, simple, and rapid test that can be performed in a wide range of clinical settings by a lay clinician or clinical assistant. One of the most important health care needs health is the ability to detect cardiac dysfunction early,” HeartSciences CEO Andrew Simpson said in a statement. “Adding diagnostic information related to cardiac dysfunction to an ECG would not only make it a screening tool much more valuable, but would also fill a significant unmet need in the market with approximately 100 million ECG tests performed each year in the United States alone.”
Important indicator of overall heart health
Diastolic dysfunction is a problem with diastole, the first part of a person’s heartbeat. It happens when the lower chambers of the heart don’t relax as they should, and over time this can lead to diastolic heart failure. It is an important indicator of overall heart health because it is altered by all common heart disease pathological processes and is a sensitive indicator of cardiovascular dysfunction. the company said.\
Currently, diastolic function of the heart must be assessed in a specialized cardiology setting, most often via echocardiography-based imaging, HeartSciences said in a statement. ECGs have had a limited, if any, role in the assessment of cardiac dysfunction and therefore the ability to assess cardiac diastolic function using an ECG would make it a more valuable cardiac screening tool. . especially in frontline clinical or point-of-care settings, the company said.
“A new era for ECGs”
“A growing body of published ECG research demonstrates that ECGs can have far greater clinical value and the granting of this patent reinforces our belief that HeartSciences is at the forefront of what should be a new era for ECGs,” Simpson said. “This latest patent is an important extension of our intellectual property portfolio, providing significant prospective value for the company.”
Chief Operating Officer Mark Hilz said the company is committed to protecting its patent rights.
“We are committed to protecting patents and intellectual property related to our research and development efforts focused on expanding ECG clinical capabilities. We believe that patent and intellectual property protection is essential, while pursuing new advances for ECGs, and we are proud to have obtained this valuable patent from the USPTO,” he said.
Eighth US patent to date; IPO closed in June
This is the company’s eighth US patent to date, and brings the company’s total number of issued patents to 18, including international ones. international jurisdictions, including Brazil, Canada, India, South Korea, Mexico and the United Arab Emirates.
In June, the company closed a public offering of $4.25 per share for aggregate gross proceeds of approximately $6.375 million.
At the time, HeartSciences said it planned to use the net proceeds of the offering primarily to fund FDA clearance for the MyoVista device, including the completion of the pivotal clinical validation study, as well as for working capital and general business purposes.
Founded in 2008
HeartSciences was founded in 2008 with a mission to provide accurate and affordable screening tools for the early detection of heart disease through the continued development of innovative electrocardiograms.
Known as the “silent killer”, heart disease is one of the leading causes of death worldwide. Most heart disease patients are unconscious and asymptomatic. Identifying these asymptomatic patients remains a major challenge in healthcare.
According to the Centers for Disease Control, approximately 697,000 people in the United States died of heart disease in 2020, representing 1 in 5 deaths. Heart disease costs the United States approximately $229 billion each year from 2017 to 2018, the CDC said, including the cost of health services, medications and lost productivity due to death.
Subscribe to the list.
Dallas innovates, every day.
Sign up to keep an eye on what’s new and coming to Dallas-Fort Worth, every day.
#HeartSciences #Brings #Diastolic #Dysfunction #Assessment #Life #Patent